Stifel Nicolaus Lowers Inspire Medical Systems (NYSE:INSP) Price Target to $65.00

Key Points

• Stifel Nicolaus lowered its price target on Inspire Medical Systems from $70 to $65 while keeping a "buy" rating, which the firm says implies roughly a 42.5% upside from the stock's current level.
• Inspire beat Q1 estimates (EPS $0.10 vs. -$0.28; revenue $204.6M) but issued a material FY2026 guidance cut to $0.75–$1.25 EPS and $825M–$875M revenue, citing reimbursement/coding issues and WISeR disruption, triggering analyst downgrades and a sharp sell-off.
• The shares traded as low as $45.60 intraday (12‑month low ~$44.41), the company has a market cap around $1.31B, and the Street consensus sits at a "Hold" with an average target near $88.56, reflecting polarized analyst views.

Inspire Medical Systems (NYSE:INSP - Get Free Report) had its price objective dropped by research analysts at Stifel Nicolaus from $70.00 to $65.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' target price points to a potential upside of 42.54% from the company's current price.

INSP has been the subject of several other reports. Morgan Stanley set a $60.00 price objective on shares of Inspire Medical Systems in a report on Wednesday, February 18th. Robert W. Baird lowered their target price on shares of Inspire Medical Systems from $63.00 to $50.00 and set a "neutral" rating on the stock in a research note on Tuesday. Mizuho lowered their target price on shares of Inspire Medical Systems from $70.00 to $55.00 and set an "outperform" rating on the stock in a research note on Tuesday. Evercore set a $55.00 target price on shares of Inspire Medical Systems in a research note on Tuesday. Finally, UBS Group set a $67.00 target price on shares of Inspire Medical Systems in a research note on Friday, February 13th. Four research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Inspire Medical Systems presently has a consensus rating of "Hold" and a consensus target price of $88.56.

Inspire Medical Systems Stock Performance

INSP traded down $9.24 during midday trading on Tuesday, reaching $45.60. The company had a trading volume of 1,439,547 shares, compared to its average volume of 1,181,208. The business has a 50-day moving average price of $56.73 and a two-hundred day moving average price of $79.64. The stock has a market cap of $1.31 billion, a PE ratio of 9.17, a P/E/G ratio of 2.92 and a beta of 0.83. Inspire Medical Systems has a 12-month low of $44.41 and a 12-month high of $163.35.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.28) by $0.38. The company had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. Inspire Medical Systems's revenue for the quarter was up 1.6% on a year-over-year basis. During the same period last year, the firm earned $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, research analysts anticipate that Inspire Medical Systems will post 1.82 earnings per share for the current year.

Hedge Funds Weigh In On Inspire Medical Systems

A number of institutional investors and hedge funds have recently made changes to their positions in INSP. Y Intercept Hong Kong Ltd raised its holdings in Inspire Medical Systems by 553.1% in the third quarter. Y Intercept Hong Kong Ltd now owns 99,049 shares of the company's stock worth $7,349,000 after buying an additional 83,883 shares during the last quarter. Illinois Municipal Retirement Fund raised its holdings in Inspire Medical Systems by 262.0% in the third quarter. Illinois Municipal Retirement Fund now owns 25,424 shares of the company's stock worth $1,886,000 after buying an additional 18,400 shares during the last quarter. Regal Partners Ltd purchased a new position in Inspire Medical Systems in the third quarter worth about $7,547,000. Aberdeen Group plc raised its holdings in Inspire Medical Systems by 16.3% in the fourth quarter. Aberdeen Group plc now owns 460,901 shares of the company's stock worth $42,509,000 after buying an additional 64,561 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in Inspire Medical Systems in the third quarter worth about $3,047,000. Institutional investors own 94.91% of the company's stock.

Key Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 results beat estimates — Inspire reported $0.10 EPS (vs. consensus loss) and $204.6M revenue, topping Street expectations and showing modest year-over-year sales growth. This supports the company's underlying business strength. GlobeNewswire: Q1 Results
• Neutral Sentiment: Analyst note: Mizuho cut its price target from $70 to $55 but kept an "outperform" rating — the new target offers almost no upside versus the current price, so it is mixed (still favorable rating but lower conviction on upside). Benzinga
• Neutral Sentiment: Company materials and call transcript are available for investors reviewing management commentary and the details behind the guidance change. Earnings Call Summary (Yahoo)
• Negative Sentiment: Guidance cut — Inspire narrowed FY2026 EPS guidance to $0.75–$1.25 (street ~$1.99) and revenue to $825M–$875M (street ~$961M). Management cited reimbursement/coding issues and WISeR disruption as drivers of the downgrade, which materially reduces expected growth and margins. Seeking Alpha: Guidance & WISeR Disruption
• Negative Sentiment: Analyst downgrades/price-target cuts — Robert W. Baird cut its target to $50 and moved to "neutral"; Bank of America reaffirmed "neutral" with a $53 target. Those moves signal reduced analyst confidence and put further pressure on the shares. The Fly: Baird Note
• Negative Sentiment: Market reaction: coverage and headlines emphasizing the guidance cut and reimbursement uncertainty drove a sharp intraday sell-off (coverage noted a large single-day decline following the update). Yahoo Finance: Stock Reaction

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.